Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – September 30, 2020
November 05, 2020 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so-called "feeding tolerance" in premature infants....
Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 30 juni 2020
August 14, 2020 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 30 juni 2020 VD Kommenterar IBT utvecklar läkemedelskandidaten IBP-9414 för att...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2020
August 14, 2020 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2020 Message from the CEO IBT is currently developing its drug candidate IBP-9414 to prevent necrotizing...
Årsstämma i Infant Bacterial Therapeutics
June 16, 2020 11:00 ET
|
Infant Bacterial Therapeutics AB
Årsstämma i Infant Bacterial Therapeutics På årsstämman i Infant Bacterial Therapeutics AB (publ) den 16 juni 2020 beslöts bland annat följande: fastställande av årsredovisningenbeviljad...
Annual General Meeting of Infant Bacterial Therapeutics
June 16, 2020 11:00 ET
|
Infant Bacterial Therapeutics AB
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on June 16, 2020, among other things, the following was resolved: adoption of the annual reportdischarge from liability...
Kallelse till årsstämma i Infant Bacterial Therapeutics
May 18, 2020 15:30 ET
|
Infant Bacterial Therapeutics AB
Aktieägarna i Infant Bacterial Therapeutics AB (publ) kallas till årsstämma tisdagen den 16 juni 2020. Mot bakgrund av coronaviruset genomförs årsstämman genom förhandsröstning med stöd av tillfälliga...
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics
May 18, 2020 15:30 ET
|
Infant Bacterial Therapeutics AB
Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Tuesday, June 16, 2020. In light of the coronavirus, the Annual General Meeting is conducted...
Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 31 mars 2020
May 11, 2020 10:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterarIBT utvecklar läkemedelskandidaten IBP-9414 för att minska förekomsten av nekrotiserande enterokolit (”NEC”), samt förbättra så kallad “feeding tolerance” hos för tidigt födda...
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1-March 31, 2020
May 11, 2020 10:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO IBT is currently developing its lead drug candidate IBP-9414 to prevent necrotizing enterocolitis (NEC), and to improve so called “feeding intolerance” affecting premature...
Infant Bacterial Therapeutics publicerar årsredovisning för 2019
April 03, 2020 08:05 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) publicerar idag årsredovisningen för räkenskapsåret 2019. Årsredovisningen finns tillgänglig på IBTs hemsida ibtherapeutics.com under avsnittet ”Investerare...